Get in touch to find out more

Thank you for your submission!

Oops! Something went wrong while submitting the form.

Peter Liu
15.8.2022 22:28

Ones to watch for in oncology

Ones to watch for in oncology

Imagine the day when all cancers can be cured - it’s the ultimate objective of cancer research. Yet according to the World Health Organisation, cancer accounted for nearly 10 million deaths, globally, in 2020 alone.

From prevention and early diagnosis, to treatment and cancer management, innovation and collaboration sit at the heart of accelerating oncology research. That’s why at Bruntwood SciTech, we teamed up with some of the biggest names in UK cancer research and clinical excellence, plus four major global pharmaceutical and healthcare companies to combine forces and help accelerate the translation of emerging cancer research into patient benefits. The Alderley Park Oncology Development Programme is working with companies and academic researchers across the UK, to help them develop their innovations more quickly and efficiently, ready to take on new funding or collaborators to accelerate the progress of their innovations commercially.

Five months into the programme, and now approaching the end of part one of the Development Phase, we’re taking a look at the eight projects who have impressed the consortium of experts and have made it through.

Oxford Cancer Analytics

Mr Andreas Halner, President and Chief Operating Officer and Dr Peter Liu, Co-Founder, both met whilst studying for their PhD. Combining Andreas’s mathematical skills and medical background with Peter’s cutting-edge oncology experience, Oxford Cancer Analytics seeks to detect cancer early and radically improve upon clinical management following cancer diagnosis, through analysis of patient blood samples with tailored machine learning tools. The company has already been able to double detection of the earliest stage of multiple cancers from sensitivity in the 40%s to a sensitivity in the 80%s, whilst maintaining specificity at 99%. Oxford Cancer Analytics is about to announce the closing of their oversubscribed seed round.

What are you looking forward to most about the next stages of the programme?

“I’m especially looking forward to exploring the multiple uses of Oxford Cancer Analytics’ assets for scientific and commercial applications we hadn’t previously envisaged and learning about uncharted regions of potential customer landscapes.”

To read the full article please visit: